Table 1.
Diseases | Abbreviations | PMID | Data source | Year | Population | N | Cases | Controls | Reference genome |
---|---|---|---|---|---|---|---|---|---|
breast cancer | BC | 32,424,353 | https://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/ | 2020 | European | 247,173 | 133,384 | 113,789 | GRCh39 (hg19) |
ER + breast cancer | ERPBC | 29,059,683 | ieu-a-1127 | 2017 | European | 175,475 | 69,501 | 105,974 | GRCh39 (hg19) |
ER- breast cancer | ERNBC | 29,059,683 | ieu-a-1128 | 2017 | European | 127,442 | 21,468 | 105,974 | GRCh39 (hg19) |
polycystic ovarian syndrome | PCOS | 30,566,500 | https://www.repository.cam.ac.uk/handle/1810/289950 | 2018 | European | 113,238 | 10,074 | 103,164 | GRCh39 (hg19) |
Overview of PCOS and BC, abbreviations as used throughout the manuscript, associated PubMed ID, Data source and Year of publication, the sample size, population and reference genome on which summary statistics are based, and the number of SNPs included in the original summary statistics, before we applied filtering